Most Recent
Cipla loses bid to cut short Novo Nordisk’s weight loss drug patent
Indian drug maker Cipla has lost a challenge to the extension of Novo Nordisk’s patent for Victoza, with a judge rejecting an argument that extensions can be granted only for active ingredients.
Monash IVF class action wants bulk of late members shut out of $56M deal
A class action on behalf of 700 patients alleging Monash IVF destroyed potentially viable embryos has told a court the majority of late registrants should not share in the $56 million settlement.
Construction PRO
Builders lose appeal over docs in spat over Royal Adelaide Hospital construction
The builders involved in Adelaide's $1.85 billion Royal Adelaide Hospital have lost their appeal of a decision blocking their bid to access documents from the state government on parliamentary privilege grounds.
High Court ends Commonwealth’s quest for $325M over generic Plavix ban
The High Court has settled a 16-year battle between the federal government and Sanofi over alleged excess subsidies it paid after a judge blocked the release of a generic version of blood thinner Plavix, saying its job was not to “resurrect” a dead case.
In latest class action loss, Bayer defeats case over Essure device
Medical device maker Bayer has successfully defended a class action over its Essure contraceptive, with a judge finding the evidence fell short of proving the device caused chronic inflammation.
Allergan hit with class action over breast implants linked to cancer
US drug company Allergan is facing a class action on behalf of women implanted with textured breast implants that were recalled after they were linked to a form of non-Hodgkin lymphoma. 
Bayer launches High Court appeal to revive Xarelto patents
Bayer has filed a High Court challenge to a decision that invalidated its patents for blockbuster blood thinner Xarelto, saying it would adversely affect drug research and development.
Pharmacor says AstraZeneca’s Brilinta patent should not have been extended
As it fends off a suit by AstraZeneca seeking to block the sale of a cheaper version of Brilinta, generics maker Pharmacor claims a patent for the heart attack drug should not have been extended.
AI pathology invention just administrative tool, not patentable: IP Australia
AI tech company Paige can't patent a tool to provide quality control for analysis of pathology images, with IP Australia finding the invention is merely an “administrative scheme” to automate the role of human pathologists.